Neurological disorders Archives

Screenshot 2016 10 21 at 12.29.43 PM e1477045913351

News and Trends 21 Oct 2016

New Partnership comes to the Rescue in Neurological Diseases

Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 18 at 5.42.27 PM e1476805403921

News and Trends 18 Oct 2016

This New Biotech wants to Regrow Neurons to cure Parkinson’s

Mavalon Therapeutics will develop a drug candidate for Parkinson’s that can stop the disease progression by activating the growth of dying neurons. Mavalon Therapeutics, born today in the UK, will be entirely dedicated to the development of a drug candidate to stop the progression of Parkinson’s. Domain Therapeutics has created this new company with a €9M investment […]

October 18, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2016

Meet the First Biotech to Jump on Autophagy After This Years’ Nobel Prize

Just after the Nobel Prize was awarded to the study of autophagy, PhoreMost announces a collaboration to target the process in neurodegenerative diseases. PhoreMost is a drug discovery company that focuses on finding ‘undruggable’ targets, such as the KRAS cancer gene. Now, the company has announced a collaboration with the University of Cambridge to start working […]

October 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […]

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

synapses neurons alzheimers Bruce Rolff fi

News and Trends 27 Sep 2016

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe observes, “Alzheimers therapies have, for the most part, been a cliff over which people push bales of money.” Unfortunately, the late-stage failure of […]

September 27, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

multiple sclerosis by decade3d anatomy online FI

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab). Phase III data shows it outperforming Merck’s Rebif, the standard therapy for MS. Competition for a new MS drug has been stiff, but new promising data from the Phase III trial of Ocrevus (ocrelizumab) suggests […]

September 15, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 14 Sep 2016

This French Startup brings Gene Therapy to Neurodegenerative Diseases

There were many exciting developments for CNS disease treatments last year, and now a French biotech is winding up to add gene therapy to the mix. BrainVectis just closed its Series A round with €1M. Paris-based BrainVectis wants to apply some of the hottest technology in biotech, gene therapy, to neurodegenerative disease, and it just […]

September 14, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 9 Sep 2016

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

A German biotech has surfaced with a promising new drug for traumatic brain injury: vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III. In news from the novel and obscure, someone has taken an interest in Nitrous Oxide Synthase (NOS). That someone is vasopharm GmbH, a small German biopharmaceutical company interested in cerebrovascular diseases. The company has […]

September 9, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

ADHD is believed to affect up to 7% of people worldwide, but some common therapies bear a shocking resemblance to Speed. A new drug from NLS, Mazindol, just entered Phase II and could set a new non-amphetaminic standard. The treatment of Attention Deficit Hyperactive Disorder (ADHD) is hotly debated in the US, were almost 10% […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Aug 2016

US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

F-star’s “plug-and-play” technology can turn any existing antibody into a full-size bispecific antibody. Denali has recognized its potential use for drug delivery to the CNS and inked a deal with the UK-based company for almost €1B. Denali (US) and F-Star (UK) have struck a deal to develop F-star’s Modular Antibody Technology™ for the generation of […]

August 26, 2016 - 2 minutesmins - By Evelyn Warner

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us